Stock Sale, Buyback News

HONG KONG--(BUSINESS WIRE)--Maven Investment Partners Ltd. Hong Kong Branch (“Maven”), one of the largest minority shareholders of MCJ Co., Ltd (“MCJ” or the “Company”) with a stake close to 3%, published a letter today addressed to all shareholders of the Company concerning the unfair terms of the tender offer (“Offer”) by BCPE Meta Cayman, L.P. (“Bain”) for MCJ. Maven confirms it has no intention of tendering into the Offer on current terms, which it views as an egregious disregard for fair M...

SAN DIEGO--(BUSINESS WIRE)--Airgain, Inc. (NASDAQ: AIRG), a leading provider of advanced wireless connectivity solutions, today announced that it has granted inducement awards to two new employees who recently joined the Company. The awards were granted on March 15, 2026, under Airgain’s 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Airgain as an inducement to join the company. The inducement awards to the new employees con...

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (“Guardian”) (NYSE: GRDN) today announced the launch of a proposed underwritten public offering (the “Offering”) of 5,000,000 shares of its Class A common stock, consisting of 3,980,000 shares being offered by certain selling stockholders and 1,020,000 newly issued shares being offered by Guardian as part of a non-dilutive “synthetic secondary” transaction, as described below. In addition, the selling stockholders intend to grant the un...

LAUSANNE, Switzerland & SAN JOSE, Calif.--(BUSINESS WIRE)--SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced that the Company’s board of directors has approved a new, three-year share buyback program which will allow the Company to use up to $1.4 billion to repurchase its shares. Together with the $600 million previously approved in March 2025, this new $1.4 billion program is in alignment with the Company’s stated...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on March 14, 2026, the company granted (i) a non-statutory stock option to purchase 1,950 shares of the company’s common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 4,375 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of t...

AMSTERDAM--(BUSINESS WIRE)--Nebius Group N.V. (“Nebius Group” or the “Company”; NASDAQ: NBIS), a leading AI infrastructure company, today announced the pricing of its offering of $4.0 billion aggregate original principal amount of convertible senior notes, in two series: $2.25 billion aggregate original principal amount of 1.250% convertible notes due 2031 (the “2031 Notes”) and $1.75 billion aggregate original principal amount of 2.625% convertible notes due 2033 (the “2033 Notes”, and togethe...

LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced a new initiative under which executives and other employees will increase their ownership in the Company through a structured share acquisition program in exchange for deferring part of their salaries. This initiative is designed to align management and employee interests more closely with...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on March 16, 2026, it granted stock options to purchase an aggregate of 58,650 shares of common stock to six ne...

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Boa...

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Diagnostics (Paris:ABLD) announces that its main shareholder, Advanced Biological Laboratories (ABL), a Luxembourg-based diagnostics company, has filed information with the French Financial Markets Authority (AMF) via ONDE, the centralized information filing system, regarding the sale of a new block of ABL Diagnostics shares as part of an over-the-counter transaction with a private third party. The filing relating to this sale can be viewed...